Phathom Pharmaceuticals, Inc. (PHAT) Investor Relations Documents

Phathom Pharmaceuticals, Inc. (PHAT) investor relations documents from the company's IR site: 5 presentations, 15 press releases; latest deck 2026-07-29. Read in-app with summaries. First-party data.

Phathom Pharmaceuticals – Corporate Overview – July 2026: Phathom Pharmaceuticals' VOQUEZNA (vonoprazan) achieved $132.6M H1 '26 revenue, with FY26 guidance of $310-325M, and expects operating profit in 2026.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-07-30Press releasePhathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-29PresentationPhathom Pharmaceuticals – Corporate Overview – July 2026
2026-07-20Press releasePhathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30
2026-06-23Press releasePhathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vo
2026-06-07DocumentDocument
2026-06-06PresentationPresentation
2026-05-22Press releasePhathom Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-05-20Press releasePhathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meet
2026-05-01Press releasePhathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
2026-04-30Press releasePhathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
2026-04-29Earnings deckFirst Quarter 2026 Earnings Call Presentation – April 2026
2026-04-20Press releasePhathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30
2026-04-06Press releasePhathom Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-02-26Press releasePhathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
2026-02-25Earnings deckFourth Quarter & Full Year 2025 Earnings Call Presentation - February 2026
2026-02-23Press releasePhathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Press releasePhathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thu
2026-02-05Press releasePhathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
Press releasePhathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
2025-10-29Earnings deckThird Quarter 2025 Earnings Call Presentation – October 2025
Press releasePhathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

PHAT overview · PHAT earnings · PHAT financials · PHAT KPIs · PHAT documents · PHAT ownership · PHAT peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.